Fletcher Spaght

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, that specializes in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics, translational, and clinical research. The company focuses on creating innovative molecular biology reagents, protocols, and diagnostic tools to enhance the efficiency and accuracy of genomic analysis. Its product offerings include various RNA and DNA library preparation kits, amplicon panels, hybridization capture kits, and specialized tools for cancer gene profiling and metagenomics. Swift Biosciences' technologies aim to streamline sample preparation processes and improve data quality from NGS instruments, supporting a wide range of applications such as circulating tumor cells and whole-genome sequencing. The company distributes its products through a network of distributors across Asia Pacific, Europe, the Middle East, and South America. Established in 2009, Swift Biosciences is committed to advancing molecular research and diagnostics.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, that specializes in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics, translational, and clinical research. The company focuses on creating innovative molecular biology reagents, protocols, and diagnostic tools to enhance the efficiency and accuracy of genomic analysis. Its product offerings include various RNA and DNA library preparation kits, amplicon panels, hybridization capture kits, and specialized tools for cancer gene profiling and metagenomics. Swift Biosciences' technologies aim to streamline sample preparation processes and improve data quality from NGS instruments, supporting a wide range of applications such as circulating tumor cells and whole-genome sequencing. The company distributes its products through a network of distributors across Asia Pacific, Europe, the Middle East, and South America. Established in 2009, Swift Biosciences is committed to advancing molecular research and diagnostics.

SurgiQuest, established in 2006 and headquartered in Orange, Connecticut, specializes in technology solutions for minimally invasive surgeries. The company's flagship product is AirSeal, a proprietary system that generates an air curtain to maintain an insufflated and airtight environment during laparoscopic and laparoscopic-assisted procedures. SurgiQuest caters primarily to bariatric, colorectal, general, gynecological, and urologic surgical disciplines.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, founded in 2007. The company specializes in developing non-viral gene therapies aimed at activating the body's natural repair processes. Its primary focus is on treating non-healing wounds in patients with advanced peripheral artery disease. The flagship product, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1), a signaling protein that helps recruit the body's stem cells and promotes tissue repair across various disease states. Juventas has transitioned its therapeutic platform from concept to the initiation of mid-stage clinical trials, underpinned by exclusive licensing from the Cleveland Clinic and supported by various investors and grants.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Cayenne Medical, Inc. is a medical device company based in Scottsdale, Arizona, specializing in soft tissue reconstruction solutions for the knee, shoulder, and extremities. Founded in 2005, the company designs and develops a range of products for arthroscopic surgery, including the AperFix System, which facilitates anterior cruciate ligament (ACL) reconstruction using various grafts. Its offerings also include the AperFix Femoral and Tibial devices for restoring knee kinematics and anatomical reconstruction. Additionally, Cayenne Medical provides the CrossFix II System for meniscal repair, the iFix Interference Screw System for ACL procedures, and a line of shoulder products under the Quattro System for various soft tissue repairs. The company's innovative solutions aim to enhance surgical precision and improve patient outcomes in sports medicine.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

SurgiQuest, established in 2006 and headquartered in Orange, Connecticut, specializes in technology solutions for minimally invasive surgeries. The company's flagship product is AirSeal, a proprietary system that generates an air curtain to maintain an insufflated and airtight environment during laparoscopic and laparoscopic-assisted procedures. SurgiQuest caters primarily to bariatric, colorectal, general, gynecological, and urologic surgical disciplines.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, specializing in precision medicine through its innovative HTG EdgeSeq platform. Established in 1997, the company offers a suite of molecular-based technology solutions for gene expression profiling and the measurement of various RNA types, including miRNA and mRNA. The HTG EdgeSeq technology automates sample processing, allowing for the rapid and simultaneous profiling of hundreds to thousands of molecular targets using minimal biological material. HTG Molecular Diagnostics markets a range of products, including instruments, assay kits, and software, which work together to facilitate efficient molecular profiling. Its offerings include several specialized panels designed for oncology and immuno-oncology applications. The company serves a diverse clientele comprising biopharmaceutical firms, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Interactive Supercomputing, Inc. was founded in 2004 and is headquartered in Waltham, Massachusetts. The company developed Star-P, an interactive parallel computing platform designed for automatic parallelization and execution of desktop simulation applications across various sectors, including biomedical, financial, and government laboratory research. Star-P enables users to perform scientific, engineering, or analytical computations on array or matrix-based data by leveraging parallel architectures such as multi-core workstations, multi-processor systems, and distributed memory clusters, as well as cloud-based environments. In addition to its software platform, Interactive Supercomputing provides customer support, professional services, application consulting, and training services. The company markets its products through authorized resellers both in the United States and internationally. In September 2009, Interactive Supercomputing was acquired by Microsoft Corporation.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

BioTrove, Inc. specializes in micro and nano-scale technology platforms designed for life science research and drug discovery. The company offers several key products, including OpenArray, which facilitates relative gene expression analysis and supports genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire platform, enabling the screening of difficult drug targets through mass spectrometry-based assay development, along with the RapidFire mass spectrometry hardware system, which serves as a detection technology for drug screening and in vitro ADME applications. Their innovative systems consist of laboratory instruments and consumables that enhance the efficiency of genomic analysis, high-throughput screening, and molecular diagnostics, thereby accelerating research processes and development across multiple scientific domains.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

GlycoFi is a biotech company focused on developing biotherapeutics utilizing glycan optimization technology. Founded in 2000 and based in Lebanon, New Hampshire, the firm specializes in a proprietary protein manufacturing process that employs engineered yeast strains to achieve precise human glycosylation. This innovative approach enables the creation of therapeutic proteins, which are essential for drug development. GlycoFi aims to build its own pipeline of products while also collaborating with other pharmaceutical companies to enhance their drug offerings. In 2006, GlycoFi became a subsidiary of Merck & Co. Inc., further expanding its capabilities in the biotherapeutics field.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Ventaira Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative inhalation products. Utilizing its proprietary electrohydrodynamic (EHD) aerosolization technology, Ventaira focuses on creating novel inhaled drugs, such as fentanyl for managing breakthrough pain and salmeterol for treating asthma.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Proteus Digital Health, Inc. was a digital medicines company headquartered in Redwood City, California, founded in 2001. It specialized in developing innovative products and services that integrated pharmaceuticals with ingestible sensors, wearable technology, mobile applications, and cloud computing. The company's offerings included ingestible sensors that communicated medication adherence, wearable sensor patches to monitor physiological responses, and digital platforms for data analytics. These technologies aimed to empower patients and their families in managing health, while providing healthcare providers with tools to enhance decision-making and optimize treatment outcomes. In November 2020, Proteus Digital Health filed for Chapter 11 bankruptcy and subsequently ceased operations.

Ventaira Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative inhalation products. Utilizing its proprietary electrohydrodynamic (EHD) aerosolization technology, Ventaira focuses on creating novel inhaled drugs, such as fentanyl for managing breakthrough pain and salmeterol for treating asthma.